SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 56 filers reported holding SPERO THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $151,250 | -16.6% | 125,000 | 0.0% | 0.05% | -6.0% |
| Q2 2023 | $181,250 | 0.0% | 125,000 | 0.0% | 0.05% | -7.4% |
| Q1 2023 | $181,250 | -16.2% | 125,000 | 0.0% | 0.05% | -11.5% |
| Q4 2022 | $216,250 | -13.5% | 125,000 | 0.0% | 0.06% | -9.0% |
| Q3 2022 | $250,000 | -77.6% | 125,000 | +25.0% | 0.07% | -81.5% |
| Q3 2020 | $1,116,000 | +186.9% | 100,000 | +107.9% | 0.36% | +124.1% |
| Q1 2020 | $389,000 | -6.9% | 48,103 | +22.1% | 0.16% | +3.2% |
| Q3 2019 | $418,000 | -48.1% | 39,395 | -43.7% | 0.16% | -48.2% |
| Q2 2019 | $806,000 | -10.1% | 70,000 | 0.0% | 0.30% | -21.7% |
| Q1 2019 | $897,000 | +108.1% | 70,000 | 0.0% | 0.39% | +80.8% |
| Q4 2018 | $431,000 | -41.4% | 70,000 | 0.0% | 0.21% | -29.1% |
| Q3 2018 | $736,000 | +74.8% | 70,000 | +136.9% | 0.30% | +47.3% |
| Q1 2018 | $421,000 | +613.6% | 29,544 | +490.9% | 0.20% | +540.6% |
| Q4 2017 | $59,000 | – | 5,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,376,968 | $17,639,000 | 16.57% |
| Aquilo Capital Management, LLC | 1,054,356 | $13,506,000 | 5.98% |
| VHCP Management II, LLC | 474,015 | $6,072,000 | 1.78% |
| AWM Investment Company, Inc. | 562,296 | $7,203,000 | 1.42% |
| Alphabet Inc. | 1,112,473 | $14,251,000 | 0.74% |
| BVF INC/IL | 460,706 | $5,902,000 | 0.66% |
| DAFNA Capital Management LLC | 70,000 | $897,000 | 0.39% |
| Artal Group S.A. | 600,000 | $7,686,000 | 0.31% |
| Rock Springs Capital Management LP | 525,000 | $6,725,000 | 0.26% |
| Orbimed Advisors | 507,471 | $6,501,000 | 0.10% |